U.S. Markets open in 5 hrs 32 mins

Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI

Stock Monitor: TapImmune Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on GTx, Inc. (NASDAQ: GTXI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GTXI as the Company's latest news hit the wire. On April 09, 2018, the Company declared that it has completed patient enrollment several months ahead of schedule in its placebo-controlled, Phase-2 clinical trial assessing enobosarm in postmenopausal women with stress urinary incontinence (SUI). The ASTRID trial enrolled 493 women at over 60 clinical trial centers across the United States. Top-line results from the trial are expected in Q4 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for TapImmune, Inc. (NASDAQ: TPIV), which also belongs to the Healthcare sector as the Company GTx, Inc. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, GTx most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Enrollment in the ASTRID Exceeded the 400 Patients Planned Per Protocol

Robert J. Wills, Ph.D., Executive Chairman of GTx, mentioned that due to overwhelming interest from women wanting to participate in the clinical trial, and the extraordinary teamwork by the clinical trial centers, enrollment in the ASTRID trial was completed in approximately eight months, with enrollment exceeding the 400 patients planned per protocol.

Robert added that the ASTRID trial has the same enrollment inclusion/exclusion criteria as the Company's enobosarm proof-of-concept clinical trial in SUI that provided the compelling data previously announced.

GTx Reported Positive Results from Enobosarm Phase-2 Proof-of-Concept Clinical Trial in Women with SUI

In September 2017, the Company announced top-line clinical trial results demonstrating that a daily dose of enobosarm 3 mg (GTx-024) substantially improved SUI in women as well as related quality of life measurements. In this open-label clinical trial, all 17 patients completing 12 weeks of treatment saw a clinically significant reduction (50% or greater) in stress leaks per day compared to baseline. Mean stress leaks decreased by 83% from baseline over 12 weeks, and the reductions in daily stress leaks following completion of treatment were sustained.

Phase-2 ASTRID Clinical Trial

The ASTRID (Assessing Enobosarm for Stress Urinary Incontinence Disorder) trial is an ongoing, placebo-controlled Phase-2 clinical trial in postmenopausal women with SUI. The rationale for evaluating enobosarm as a treatment for SUI is supported by a Phase-2 proof-of-concept clinical trial, the results of which were outlined in March 2018, and preclinical in vivo data demonstrating increases in pelvic floor muscle mass following treatment with GTx's SARM compounds, including enobosarm.

About Stress Urinary Incontinence

SUI is a serious condition where the unintentional leakage of urine occurs during normal daily activities with increased abdominal pressure (such as coughing, sneezing, running, or lifting heavy objects). This inability to control urine flow occurs when the involved sphincter and support muscles become weak or do not function properly. Women suffer more frequently from SUI because the most common causes include childbirth or other injury to the short urethral area. SUI can occur in young women after childbirth but becomes more prevalent around the time of menopause in women.

About Enobosarm

Enobosarm, also known as ostarine, is an investigational selective androgen receptor modulator (SARM) developed by GTx for the treatment of conditions such as muscle wasting and osteoporosis. Enobosarm has been evaluated in 25 completed or ongoing clinical trials. These clinical trials have enrolled over 2,100 subjects, of which approximately 1,500 subjects were treated with enobosarm at doses ranging from 0.1 mg to 100 mg. At all evaluated dose levels, enobosarm was observed to be generally safe and well tolerated.

About GTx, Inc.

Headquartered in Memphis, Tennessee, GTx is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions.

Stock Performance Snapshot

April 10, 2018 - At Tuesday's closing bell, GTx's stock declined 1.01%, ending the trading session at $18.58.

Volume traded for the day: 36.07 thousand shares.

Stock performance in the last three-month – up 67.99%; previous six-month period – up 126.86%; past twelve-month period – up 312.89%; and year-to-date - up 46.18%

After yesterday's close, GTx's market cap was at $418.79 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.8% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors